Should You Buy Tilray Stock Before July 15?

On July 15, the DEA will conclude its hearing on rescheduling cannabis from Schedule I to Schedule III. While Tilray doesn't directly operate U.S. cannabis businesses and won't immediately benefit from tax relief, the company is well-positioned for long-term cannabis reform with its diversified international medical cannabis business, craft beverages, and wellness products. With $630M in revenue and $265M in cash, investors should focus on multi-year reform prospects rather than short-term headline reactions.